Unknown Manufacturer
Ancrod is an anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country.
Ancrod is an anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country.
Ancrod's anticoagulant effects are through the rapid removal of fibrinogen from the blood within hours following ancrod administration. Ancrod specifically cleaves only the alpha chain of fibrinogen, producing the characteristic fibrinopeptides A, AP and AY, not the B-fibrinopeptide. The resulting fibrin polymers are imperfectly formed and much smaller in size (1 to 2 µm long) than the fibrin polymers produced by the action of thrombin. These ancrod-induced microthrombi are friable, unstable, urea-soluble and have significantly degraded a-chains. They do not cross-link to form thrombi. They are markedly susceptible to digestion by plasmin and are rapidly removed from circulation by either reticuloendothelial phagocytosis or normal fibrinolysis, or both. Blood viscosity is reduced by 30-40%. Ancrod does not activate plagminogen and does not degrade preformed, fully cross-linked thrombin fibrin. Consequently, unlike fibrinolytic agents, ancrod can be used postoperatively. Ancrod does not activate Factor XIII, produce platelet aggregation, or release ADP, ATP, potassium, or serotonin from platelets.
治疗各种血栓栓塞性疾病，如深部静脉血栓、心肌梗死、肺梗死、周围动脉闭塞和视网膜中心静脉血栓等，并可用于手术后血栓的预防。
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
